

## THURSDAY 10 SEPTEMBER, 2020

### Opening of the Conference

*Chairs: Mark Nelson & Manal El-Sayed*

- 2:30 PM **Opening Remarks**  
**Conference Chairs**
- 2:35 PM **Viral Hepatitis B & C Elimination in 2030**  
**Olufunmilayo Lesi, MD, MBA, FMCP, FWACP**  
World Health Organization Regional Office for Africa, Congo
- 2:55 PM **Access to Treatment in Africa**  
**Oriel Fernandes**  
Clinton Health Access Initiative, USA
- 3:15 PM **Local Situation on Liver Disease in Senegal**  
**Papa Saliou Mbaye, MD**  
Principal Hospital, Senegal
- 3:20 PM **Panel Discussion**  
**Olufunmilayo Lesi, MD, MBA, FMCP, FWACP**  
World Health Organization Regional Office for Africa, Congo  
**Oriel Fernandes**  
Clinton Health Access Initiative, USA  
**Papa Saliou Mbaye, MD**  
Principal Hospital, Senegal  
**Kenneth Kabagambe**  
National Organization for People Living with Hepatitis B, Uganda

3:40 PM Coffee Break & Poster Viewing

### Symposium Slot / 45 minutes

3:50 PM **TBC**  
**TBC**

### Session 1 Prevention of Transmission; Looking after Mother and Child

*Chairs:*

- 4:35 PM **State-of-the-Art Lecture on Birth Dose Vaccination and Screening of Pregnant Women**  
**Maud Lemoine, MD, PhD**  
Imperial College London, United Kingdom
- 4:55 PM **Preventing Mother -to-Child Transmission of HBV and WHO PMTCT recommendations**  
**Ramatoulie Njie**  
University of the Gambia / International Agency for Research on Cancer, The Gambia
- 5:15 PM **Panel Discussion**  
**Maud Lemoine, MD, PhD**  
Imperial College London, United Kingdom  
**Ramatoulie Njie**  
University of the Gambia / International Agency for Research on Cancer. The Gambia  
**Manal El-Sayed, MD, PhD**  
Ain Shams University, Egypt



# Program

5:35 PM Coffee Break

## NGO Slot - FIND

5:45 PM **TBC**  
**TBC**

6:15 PM **Oral Abstract Presentations 1**  
Diagnostics and Investigation

- |  |   |
|--|---|
| Assessment of Non-Invasive Markers of Liver Fibrosis in Patients with Chronic Hepatitis C in Ethiopia  | #1 Hailemichael Desalegn, Ethiopia      |
| Fibroscan Findings in Patients with Chronic Liver Diseases in Rwanda   | #2 Zainab Ingabire, Rwanda              |
| Evaluation de la Détection de l'AgHBe pour l'Identification des Charges Virales Élevées du Virus de l'Hépatite B Exposant au Risque de Transmission Mère Enfant Malgré la Vaccination à la Naissance | #3 Nanelin Alice Guingane, Burkina Faso |
| Panel Discussion   |   |

6:45 PM **Oral Abstract Presentations 2**  
Viral Hepatitis Infections (Elimination / Prevention / Treatment / Clinical) - HBV

- |  |  |
|--|--|
| Résistance du VHB aux Inhibiteurs Nucléo(s)tidiques de la Transcriptase Inverse (INTI) et son Impact sur l'Antigène de Surface (AgHBs) chez des Patients Co-Infectés VHB-VIH à Abidjan | #4 Leto Olivier Gogbe, Côte d'Ivoire   |
| Experience of the First Hepatitis B Program in Rural Sierra Leone: One Year of Successes and Challenges  | #5 Marta Maria Patino Rodriguez, Spain |
| Frequency of Occult Hepatitis B Virus among Blood Donors in Khartoum State, Sudan: a Preliminary Study.  | #6 Mustafa Yassin, Sudan               |
| "Hepatitis B Awareness and Perceptions Among Healthcare Workers Across Africa: Report From the African Hepatitis B Network   | #7 Jose Debes, United States           |
| Panel Discussion   |  |

7:15 PM End of Day 1



## FRIDAY 11 SEPTEMBER, 2020

### Session 2 Management of Viral Hepatitis (I) - HBV related

*Chairs:*

- 2:30 PM **Management of HBV - Test & Treat Strategy**  
**Hailemichael Desalegn, MD**  
 St. Paul's Hospital Millennium Medical College, Ethiopia
- 2:50 PM **Management of HBV in Children**  
**Manal El-Sayed, MD, PhD**  
 Ain Shams University, Egypt
- 3:10 PM **Panel Discussion - HBV Care Models in Africa**  
*Moderator - Geoffrey Dusheiko, MD, MB, BCh,*  
**Hailemichael Desalegn, MD**  
 St. Paul's Hospital Millennium Medical College, Ethiopia  
**Manal El-Sayed, MD, PhD**  
 Ain Shams University, Egypt  
**Yvonne Nartey**  
 Cape Coast Teaching Hospital, Ghana  
**Reena Shah, MD**  
 Aga Khan University, Kenya

3:30 PM Coffee Break

### Session 3 Management of Viral Hepatitis (III) - HCV related

*Chairs:*

- 3:40 PM **HCV Elimination in Africa: Current Situation in the Time of DAAs**  
**Sabin Nsanzimana, MD**  
 Rwanda Biomedical Center, Rwanda
- 4:00 PM **Inclusion of vulnerable groups in HCV Prevention, Testing, and Treatment in the African Region**  
**Niklas Luhmann**  
 World Health Organization, Switzerland
- 4:20 PM **Panel Discussion**  
**Sabin Nsanzimana, MD**  
 Rwanda Biomedical Center, Rwanda  
**Niklas Luhmann**  
 World Health Organization, Switzerland  
**Zaid Heetun**  
 Dr Abdool Gaffoor Jeetoo Hospital, Mauritius  
**1 Other panellist TBD**

4:40 PM Coffee Break

## HBV Cure Science 101 - ICE-HBV

Chair: Manal El-Sayed

4:50 PM **Panel Discussion**  
**TBC**  
TBC

5:20 PM Coffee Break

5:30 PM **Oral Abstract Presentations 3**  
Complications of end stage liver disease

DNA Methyltransferases as Potential Biomarkers of HCV Related Hepatocellular Carcinoma

#8 Eman Abdelsameea, Egypt

Hepatocellular Carcinoma in Senegal : Epidemiological, Clinical and Etiological Aspects about 229 Cases at Hopital Principal de Dakar

#9 Ibrahima Diallo, Senegal

Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: a Prospective Cohort Study

#10 Edford Sinkala, Zambia

Panel Discussion

6:00 PM **Oral Abstract Presentations 4**  
Viral Hepatitis Infections (Elimination / Prevention / Treatment / Clinical) - HCV

Seroprevalence and Molecular Epidemiology of Hepatitis C in Malawi: A Cross-Sectional Community Census-Based Serological Survey of Ndriande, Blantyre

#11 Alexander Stockdale, United Kingdom

Prevalence of Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive Patients in Cameroon

#12 Marie Amougou Atsama, Cameroon

Hépatite Virale C Chronique : Efficacité et Tolérance des Antiviraux à Action Directe au Centre Hospitalier Universitaire Yalgado Ouédraogo.

#13 Jamila bdouramane Soli, Burkina Faso

Prevalence of Occult Hepatitis C Virus Infection among Egyptian Haemodialysis Patients: A Single Centre Study

#14 Tari George Michael, Egypt

Panel Discussion

6:30 PM End of Day 2



## SATURDAY 12 SEPTEMBER, 2020

### Session 4 NAFLD/NASH Management in Africa

*Chairs:*

- 2:30 PM **NAFLD/NASH Policies and Practice in Sub-Saharan Africa**  
**Jeffrey Lazarus, PhD, MIH, MA**  
 Barcelona Institute for Global Health, Spain
- 2:50 PM **Diabetes, Obesity, and COVID-19**  
**Joel Dave, MD, PHD**  
 UCT Private Academic Hospital, South Africa
- 3:10 PM **Fat and the Liver in the African Population**  
**Ponsiano Ocama, MBChB, MMED, PhD, FCP(ECSA)**  
 Makerere University College of Health Sciences, Uganda
- 3:30 PM **Panel Discussion**  
**Jeffrey Lazarus, PhD, MIH, MA**  
 Barcelona Institute for Global Health, Spain  
**Joel Dave, MD, PHD**  
 UCT Private Academic Hospital, South Africa  
**Ponsiano Ocama, MBChB, MMED, PhD, FCP(ECSA)**  
 Makerere University College of Health Sciences, Uganda  
**Mark Sonderup, B Pharm, MBChB, FCP(SA), MMED**  
 University of Cape Town, South Africa

3:50 PM Coffee Break

### Session 5 End-Stage Liver Disease (ESLD)

*Chairs:*

- 4:00 PM **Particularities of HCC in Africa**  
**Lewis Roberts, MB, Chb, PhD**  
 Mayo Clinic, USA
- 4:20 PM **Feasibility of Liver Transplantation in Africa**  
**Mahmoud El-Meteini, MD**  
 Ain Shams University, Egypt
- 4:40 PM **Panel Discussion**  
**Lewis Roberts, MB, Chb, PhD**  
 Mayo Clinic, USA  
**Mahmoud El-Meteini, MD**  
 Ain Shams University, Egypt  
**Kosh Agarwal, MD, FRCP**  
 King's College Hospital, United Kingdom  
**Edith Okeke, BMBCh, FWACP, FRCP**  
 University of Jos / Jos University Teaching Hospital, Nigeria  
**Ashraf Omar, MD**  
 Cairo University, Egypt



# Program

5:00 PM Coffee Break

## **Session 6 Hepatitis Care in Times of the COVID-19 Pandemic**

*Chairs:*

5:10 PM **Impact of COVID-19 on the Existing Elimination Programs**

**John Ward, MD**

Centers for Disease Control and Prevention / Task Force for Global Health, USA

5:30 PM **Community Experience while Delivering Hepatitis B Services during the Pandemic**

**Arafat Bwambale**

Great Lakes Peace Centre, Uganda

5:50 PM **Panel Discussion**

**John Ward, MD**

Centers for Disease Control and Prevention / Task Force for Global Health, USA

**Arafat Bwambale**

Great Lakes Peace Centre, Uganda

**Cary James**

World Hepatitis Alliance, United Kingdom

**Wendy Spearman, MD, PhD**

University of Cape Town, South Africa

6:10 PM **Closure of the Conference**

